Lpath to present clinical results of iSONEP drug in wet-AMD patients

Lpath, Inc. (OTCBB: LPTN), the category leader in therapeutic agents against bioactive lipids, will present at the 2009 BIOCOM Investor Conference, which will be held October 26-27, 2009 at the Hyatt Regency La Jolla in San Diego, California.

Lpath president and CEO Scott R. Pancoast is scheduled to present on Monday, October 26th at 11:00 a.m. Pacific time (2:00 p.m. Eastern time), followed by a break-out Q&A session and one-on-one meetings.

As part of his presentation, Pancoast will present the recent clinical results from one of the company's leading drug candidates, iSONEP™, which was well tolerated at all dose levels in a Phase 1 trial in wet-AMD patients. As previously disclosed in the company's October 8, 2009 press release, many of the patients exhibited positive biological effects largely independent of the effects seen when wet-AMD patients undergo treatment with currently approved therapies.

The presentation will be available via live webcast and replay at:> For more information on the BIOCOM Investor Conference, please visit the conference website at www.biocom.org/event/2009_Investor_Conference.